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Renal Sympathetic Denervation In Patients With Resistant Hypertension -
Inducing An Immediate And Persisting 24h Ambulatory Blood Pressure (ABPM)
Reduction – Results From The Halle-RDN-Registry
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Background: Catheter-based renal sympathetic denervation (RDN) has shown to
signiﬁcantly reduce blood pressure (BP) in patients with resistant hypertension. So far,
current available data are almost entirely derived from ofﬁce-based blood pressure
measurements (OBPM) with only few data basing on more reliable 24h ambulatory
blood pressure monitoring (ABPM).
Methods: Our study carefully investigated the ABPM response to RDN in a cohort
of 181 consecutively treated patients with resistant hypertension. Baseline values
included a mean age of 63 9.6 years, BMI of 31.9 5.8 Kg/m2, 48% women,
48% diabetic, 19% coronary artery disease and 5.7 1.8 antihypertensive medi-
cations. A 24h BP monitoring was recorded in every patient 24h before as well as
24h, 3, 6 and 12 months after RDN. BP readings were then averaged according
to daytime (7:00am-22:00pm), nighttime (22:00pm-7:00am) and 24 hours inter-
vals. All data were statistically analyzed using mixed models with repeated
measurements.
Results: In treated patients averaged systolic 24h BP was reduced by 10.341.32
mmHg (p<0.001; n 181) during the ﬁrst 24 hours. Systolic blood pressure reduction
appeared to be much higher at daytime (13.111.4 mm HG; p<0.001) compared to
nighttime (5.31.46 mm Hg; p¼0.0016) which most likely reﬂects the physiologi-
cally higher sympathetic activity at daytime. A concordant effect on diastolic BP was
observed: 6.870.76 mmHg (p<0.001). Systolic BP reduction sustained at 3
(5.631.48 mm Hg, p<0.005, n 147), 6 (4.871.5 mm Hg, p¼0.0014, n 136) and 12
months (7.591.82 mm Hg, p<0.001, n 101) without further decrease – on the
contrary a slight relapse to higher BP was seen.
Conclusions: In patients with resistant hypertension, RDN leads to an immediate and
persisting reduction of systolic and diastolic ABPM. Compared to OBPM data,
ABPM effects are expectedly less pronounced. A gradual drop in BP up to 6 months
was not seen. On the contrary a slight compensation of BP reduction was observed
after the initial drop and the 3, 6 and 12 months follow-ups. RDN may seem to
provide an acute as well as chronic therapeutic option to hypertensive Patients at risk.
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Background: Hypertension is highly prevalent and a major risk factor for coro-
nary artery disease, myocardial infarction, and stroke. Approximately 5-10% of
patients with high blood pressure are resistant to drug treatment. In these patients,
renal denervation (RD) offers an invasive approach to target the renal sympathetic
nerves and to hereby reduce blood pressure. To date, the efﬁcacy of RD has been
shown in patients with resistant hypertension and a systolic blood pressure (SBP)
 160mmHg ( 150mmHg for diabetes type 2 patients), despite treatment with
at least 3 antihypertensive drugs (including a diuretic). We therefore investigated
the effect of RDN on blood pressure in patients with less distinct resistant
hypertension.
Methods: Eligible patients were older than 18 years and had resistant hypertension
with an SBP of  135mmHg in the presence of at least 3 antihypertensive drugs
(including a diuretic). We investigated 20 patients and performed RDN using the
Simplicity catheter (Ardian, Palo Alto, California). Up to 8 ablations at 8 watt for 2
minutes were performed in both renal arteries. Blood pressure was measures at
baseline, at 3-month follow-up, and at 6-month follow-up.
Results: The mean age in the study population was 65  8.2 years. On average,
patients were taking 5.1 different antihypertensive drugs. The mean SBP was
148mmHg ( 10mmHg) at baseline. RD signiﬁcantly reduced SBP (-14.2mmHg at 3-
month follow-up, p¼0.016, and -22mmHg at 6-month follow-up, p¼0.014). Diastolic
blood pressure (75  8mmHg at baseline) did not change signiﬁcantly.
Conclusions: In patients with resistant hypertension and a SBP  135mmHg despite
treatment with at least 3 antihypertensive drugs, we demonstrate that RD is feasible
and signiﬁcantly reduces SBP. To achieve blood pressure treatment goals, RD should
therefore be taken into therapeutic considerations also in these patients. Further studies
are needed to investigate possible prognostic beneﬁts.
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venous administration of medications such as morphine and midazolam, which is
often not fully effective and is associated with potential side effects.
Methods: The Bullfrog Micro-Infusion Catheter (Mercator MedSystems, CA, USA)
consists of a perpendicular microneedle which is contained within a semi-rigid
polymer actuator. It can be introduced to the target renal artery over a 0.014" guide
wire prior to the denervation sequences on each side. A compliant stabilizing balloon
inﬂates to provide a force opposite the needle tip for proper seating of the needle,
through which anesthetic agent can be delivered to the adventitia and perivascular
tissue. A 1:1 mixture of 1% Lidocaine and intravenous contrast was used for localized
injection. Adequacy of agent delivery was determined by the presence of circumfer-
ential contrast distribution around the renal artery on ﬂuoroscopy.Results: Site-speciﬁc delivery of anesthetic agent was performed in 4 patients
undergoing renal denervation (3 radiofrequency-based and 1 ultrasound-based). Low
dose midazolam was given for 1 patient at the start of the procedure. No intravenous
midazolam or morphine was necessary for the remaining patients. No denervation-
speciﬁc pain was reported. Final renal angiography showed no signiﬁcant spasm or
dissection. All patients were discharged on the following day.
Conclusions: Site-speciﬁc administration of anesthetic agent may be a feasible
strategy to achieve optimal pain control in patients undergoing renal denervation for
treatment-resistant hypertension.
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Background: Renal denervation (RDN) has been shown to be safe and effective in
reducing blood pressure in select patients with resistant hypertension. Upcoming trials
aim to examine its use for more moderate manifestations of resistant hypertension. We
sought to determine the impact of broadening the eligibility criteria used in prior RDN
studies on the number of patients who could be eligible for RDN, and to compare the
clinical characteristics of RDN eligible versus non-eligible hypertensive patients in
a ﬁxed population of hypertensive outpatients.
Methods: We applied methodologic criteria from the SYMPLICITY HTN-3 study to
consecutive hypertensive outpatients presenting to an academic cardiology clinic to
identify patients eligible for RDN. Inclusion criteria were as follows: age >18 and
<80 years old, systolic BP> 60, on 33 anti-hypertensive medications at maximal
doses of which one was a diuretic, and creatinine clearance >45. We then examined
the impact on eligibility for RDN of including patients with systolic BP>140 and
creatinine clearance>30. Patients with renal arterial stenosis, or noncompliance were
excluded. Demographic and clinical characteristics of patients were compared
between those who did and did not meet criteria for RDN.
Results: We identiﬁed 1756 hypertensive outpatients; they were predominantly male
(54.9%) and white (53.2%), had a mean age of 66.612.6 years, and a BMI of
30.110.8 kg/m2. Only 22 of these patients (1.3%) would be eligible for RDN under
SYMPLICITY HTN-3 criteria. Among these patients, 16 (72.2%) were female and 20
(90.9%) were black, with a mean age of 68.910.4 and BMI of 33.26.8. Expanding
eligibility for RDN to include patients with SBP>140 and CrCl>30 lead to a near
three-fold increase in eligible patients (53 patients or 3.0%).
Conclusions: Patients meeting criteria for RDN based on existing published studies
represent an exceedingly small proportion of the total hypertensive population.
Broadening inclusion criteria, while still only relevant to only a small proportion of the
total hypertensive population, but a 375% increase over what prior studies would
predict.
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